Annual Cash & Cash Equivalents
$128.10 M
+$73.19 M+133.28%
31 December 2023
Summary:
Monte Rosa Therapeutics annual cash & cash equivalents is currently $128.10 million, with the most recent change of +$73.19 million (+133.28%) on 31 December 2023. During the last 3 years, it has risen by +$86.40 million (+207.20%). GLUE annual cash & cash equivalents is now -62.98% below its all-time high of $346.07 million, reached on 31 December 2021.GLUE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$125.58 M
+$16.73 M+15.37%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly cash and cash equivalents is currently $125.58 million, with the most recent change of +$16.73 million (+15.37%) on 30 September 2024. Over the past year, it has increased by +$66.52 million (+112.64%). GLUE quarterly cash and cash equivalents is now -65.79% below its all-time high of $367.03 million, reached on 30 September 2021.GLUE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +133.3% | +112.6% |
| 3 y3 years | +207.2% | -65.8% |
| 5 y5 years | - | - |
GLUE Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -63.0% | +207.2% | -65.8% | +167.0% |
| 5 y | 5 years | -63.0% | +2036.8% | -65.8% | +201.2% |
| alltime | all time | -63.0% | +2036.8% | -65.8% | +201.2% |
Monte Rosa Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $125.58 M(+15.4%) |
| June 2024 | - | $108.85 M(+9.1%) |
| Mar 2024 | - | $99.75 M(-22.1%) |
| Dec 2023 | $128.10 M(+133.3%) | $128.10 M(+116.9%) |
| Sept 2023 | - | $59.05 M(+25.6%) |
| June 2023 | - | $47.03 M(-9.3%) |
| Mar 2023 | - | $51.85 M(-5.6%) |
| Dec 2022 | $54.91 M | $54.91 M(-51.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $112.39 M(+8.4%) |
| June 2022 | - | $103.66 M(-25.0%) |
| Mar 2022 | - | $138.31 M(-60.0%) |
| Dec 2021 | $346.07 M(+729.9%) | $346.07 M(-5.7%) |
| Sept 2021 | - | $367.03 M(+2.8%) |
| June 2021 | - | $357.06 M(+112.0%) |
| Mar 2021 | - | $168.44 M(+303.9%) |
| Dec 2020 | $41.70 M(+595.6%) | $41.70 M |
| Dec 2019 | $6.00 M | - |
FAQ
- What is Monte Rosa Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual cash & cash equivalents year-on-year change?
- What is Monte Rosa Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Monte Rosa Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of GLUE is $128.10 M
What is the all time high annual cash & cash equivalents for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual cash & cash equivalents is $346.07 M
What is Monte Rosa Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, GLUE annual cash & cash equivalents has changed by +$73.19 M (+133.28%)
What is Monte Rosa Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of GLUE is $125.58 M
What is the all time high quarterly cash and cash equivalents for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly cash and cash equivalents is $367.03 M
What is Monte Rosa Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, GLUE quarterly cash and cash equivalents has changed by +$66.52 M (+112.64%)